1. Home
  2. G vs GKOS Comparison

G vs GKOS Comparison

Compare G & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genpact Limited

G

Genpact Limited

HOLD

Current Price

$35.51

Market Cap

6.3B

ML Signal

HOLD

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$120.70

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
G
GKOS
Founded
1997
1998
Country
Bermuda
United States
Employees
140000
N/A
Industry
Professional Services
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.3B
6.0B
IPO Year
2007
2015

Fundamental Metrics

Financial Performance
Metric
G
GKOS
Price
$35.51
$120.70
Analyst Decision
Buy
Strong Buy
Analyst Count
6
14
Target Price
$49.50
$133.07
AVG Volume (30 Days)
2.0M
637.6K
Earning Date
05-07-2026
04-29-2026
Dividend Yield
2.11%
N/A
EPS Growth
9.82
N/A
EPS
3.13
N/A
Revenue
$2,279,438,000.00
$507,442,000.00
Revenue This Year
$9.23
$23.30
Revenue Next Year
$7.26
$27.43
P/E Ratio
$11.34
N/A
Revenue Growth
N/A
32.33
52 Week Low
$33.92
$73.16
52 Week High
$50.24
$130.23

Technical Indicators

Market Signals
Indicator
G
GKOS
Relative Strength Index (RSI) 37.66 63.24
Support Level $34.79 $81.54
Resistance Level $45.77 $123.16
Average True Range (ATR) 1.24 4.49
MACD -0.15 1.62
Stochastic Oscillator 34.19 91.29

Price Performance

Historical Comparison
G
GKOS

About G Genpact Limited

Genpact Ltd is an agentic, technology-solutions company offering digital transformation, data-driven operations, and technology-enabled services across multiple industries. Its core business services include decision support services; technology services like application lifecycle management, platform customization, and support, etc; and digital operations optimizing business processes. Genpact also offers data engineering, data management, and domain-based AI and generative AI solutions; develops new technology solutions for clients; and offers agentic solutions and technology consulting services. Its reportable segments are: High Tech and Manufacturing, which generate maximum revenue, Financial Services, and Consumer and Healthcare. Geographically, it derives maximum revenue from India.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: